Natco Pharma Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6h7g5p4f6mnk3ap9qesfzzpk.pdf

Key Takeaways


Earnings Quality & Diversification

Rajeev Nannapaneni: "I think the market appreciates more steady earnings, which are low risk, and they give a higher multiple for that. And I think our market is unwilling to appreciate high-risk, high-return sort of ideas."

US Generics & The FTF Model

Rajeev Nannapaneni: "Because there were 5 and 6 competitors, the price erosion was quite steep. So, even though we had 180 days, the earnings bump was not too substantial that could move the earnings. It is the way it is. That is the nature of business."

International Markets

Rajeev Nannapaneni: "We have some big launches coming up in ‘2027. So, we expect ‘2027 will be a blowout year in Canada."

India Domestic & Semaglutide

Rajeev Nannapaneni: "But is it profitable? No. And do I see any profits coming in the near future? No. In the long run, maybe. I think it should do well as the size of Sema increases."

Capital Allocation & M&A

Rajeev Nannapaneni: "I think the asset is so valuable that 49% also is very meaningful. That’s why we took it."

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 PAT₹775 to ₹800 crores (raised from ₹700–750 crores); Q3 looks good, Q4 is a little weakFY27
FY27 R&D spend8–10% of top line, around ₹300–350 croreFY27
Operating marginCurrent level (~30.4% in Q2) considered a sustainable base going forwardOngoing
Crop Health Sciences demergerMid-year Calendar Year 2027, subject to SEBI resubmission and NCLT processMid-CY2027
FY28 base business growthAround 10%–15%, excluding uncertain upsides from Para IVs, one-times, or exclusivitiesFY28
Domestic business growthInternal target to compound 15%–20% next yearFY28
CanadaBig launches coming; 2027 expected to be a blowout year2027
CapEx run rateAround ₹400 crore per yearOngoing
Cartridge line (semaglutide)Ready next financial yearFY28
Adcock steady-state PAT pickup (consol)₹55–60 crores after 49% share and ₹4–5 crore amortizationSteady-state
Full-year standalone tax rate27%–27.2%FY27
Full-year consolidated tax rate29%–30%FY27
India business DSOExpected to continue in 90–120 day rangeOngoing

Key Metrics

MetricQ2 FY27
Consolidated total revenue₹1,019.4 cr, +28.4% QoQ vs ₹794 cr in Q1 FY27; -30.3% YoY vs ₹1,463 cr in Q2 FY26
EBITDA including other income₹310 cr, EBITDA margin of 30.4%
Consolidated profit after tax₹202.6 cr, -1.9% QoQ vs ₹206.5 cr in Q1 FY27
Domestic formulation revenue₹145 cr, includes non-repeatable Semaglutide stocking; base run rate estimated at ₹130-135 cr
Brazil business revenue₹121 cr, +66% YoY
Brazil H1 FY27 revenuenearly ₹300 cr
Adcock Ingram Q2 revenue₹1,344 cr
Adcock Ingram Q2 PAT₹80.5 cr
NATCO share of Adcock profit₹29.2 cr, based on 49% holding after purchase price allocation adjustment
Adcock stake49%, increased from 35.75% after acquiring additional 13.25% in July 2026
FY27 PAT guidance (revised)₹775 to ₹800 cr, raised from earlier ₹700-750 cr
India Semaglutide volume share5% to 6% (management estimate)
India Semaglutide value share3% (management estimate)
Crop Health Sciences Q2 EBITDAmarginal profitability, approximately ₹10 lakh segmental profit
Agro business full-year EBITDA loss expectation~₹20 cr
R&D spend FY27 guidance₹300 to ₹350 cr, 8-10% of top line
CapEx H1 FY27~₹300 cr
Full-year CapEx target~₹400 cr, typical run rate ₹350-400 cr
Net cash position~₹2,250 cr, after rights issue inflows and full loan repayment
Rights issue dilution10% overall
Consolidated tax rate Q2~29%; full-year expected 29%-30%
Standalone tax rate Q2~27%; full-year expected 27%-27.2%
India business DSO90-120 days
Investment in eGenesisless than $25 million, substantial single-digit stake